Teleflex Incorporated (TFX)
| Market Cap | 10.01B |
| Revenue (ttm) | 3.00B |
| Net Income (ttm) | 294.87M |
| Shares Out | 47.10M |
| EPS (ttm) | 6.22 |
| PE Ratio | 34.18 |
| Forward PE | 14.92 |
| Dividend | $1.36 (0.64%) |
| Ex-Dividend Date | May 14, 2024 |
| Volume | 400,344 |
| Open | 208.92 |
| Previous Close | 206.98 |
| Day's Range | 207.71 - 213.92 |
| 52-Week Range | 177.63 - 262.97 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 252.89 (+18.94%) |
| Earnings Date | May 2, 2024 |
About TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional prod... [Read more]
Financial Performance
In 2023, Teleflex's revenue was $2.97 billion, an increase of 6.57% compared to the previous year's $2.79 billion. Earnings were $356.33 million, a decrease of -1.88%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for TFX stock is "Buy." The 12-month stock price forecast is $252.89, which is an increase of 18.94% from the latest price.
News
Teleflex Publishes 2023 Global Impact Report
Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program
Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray
The First and Only Sterile, Single-Use IO Tray Cleared by the U.S. Food and Drug Administration The First and Only Sterile, Single-Use IO Tray Cleared by the U.S. Food and Drug Administration
Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPH
WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 America...
Teleflex Announces Quarterly Dividend
WAYNE, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of ...
Teleflex beats quarterly profit estimates on healthy demand for medical devices
Teleflex reported a better-than-expected first-quarter profit on Thursday, on the back of strong demand for its medical devices.
Teleflex Reports First Quarter Financial Results and Full Year 2024 Outlook
WAYNE, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2024.
Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
WAYNE, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of multiple clinical studies at the 2024 Ameri...
Teleflex Announces the Limited Market Release of the Wattson™ Temporary Pacing Guidewire
Company expands structural heart portfolio and begins the limited market release of a bipolar temporary pacing guidewire intended to introduce and position catheters and other interventional devices w...
Teleflex to Present at the BofA Securities 2024 Health Care Conference
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the BofA Securities 2024 Health Care Conference at t...
Teleflex Announces First Quarter 2024 Earnings Conference Call Information
WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m...
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tis...
Teleflex's Climate Targets Validated by the Science Based Targets Initiative
Teleflex commits to reach net-zero greenhouse gas emissions across its value chain by 2050. Teleflex commits to reach net-zero greenhouse gas emissions across its value chain by 2050.
Glancy Prongay & Murray LLP Announces Investigation of Teleflex Incorporated (TFX)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors' and officers' possible violati...
Teleflex beats quarterly profit estimates on strong demand for medical devices
Teleflex reported fourth-quarter profit above Wall Street estimates on Thursday, on the back of strong demand for its medical devices and surgical equipment.
Teleflex Reports Fourth Quarter and Full Year 2023 Financial Results
WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2023. Fourth quarter financi...
Teleflex to Present at the 45th Annual Raymond James Institutional Investors Conference
WAYNE, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 45th Annual Raymond James Institutional Investors...
Teleflex Announces Fourth Quarter 2023 Earnings Conference Call Information
WAYNE, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m...
Teleflex now offers its Titan SGS™ Stapler with Staple Line Reinforcement
A New Choice for Bariatric Surgeons: Titan SGS ™ Standard Staple Line Reinforcement with GORE ® SEAMGUARD ® Bioabsorbable Staple Line Reinforcement
Teleflex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WAYNE, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 42nd Annual J.P. Morgan Healthcare Conference at ...
Teleflex Awarded Peripheral Access Agreement with Premier, Inc.
WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agre...
Should You Pick Teleflex Stock After 20% Gains This Month?
Teleflex stock (NYSE: TFX), which provides instruments and consumables for laboratories, trades at $220 per share, 50% below the level seen in March 2021.
Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry
Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper Vascular Access Registry Intends to Examine Contemporary ...
Large-Scale Real-World Study Demystifies UroLift™ System Durability and Reinforces Superior Patient Experience for Men With Enlarged Prostate Compared to Leading Surgical Treatments
WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...
Teleflex to Present at the 35th Annual Piper Sandler Healthcare Conference
WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 35th Annual Piper Sandler Healthcare Conference a...
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.